ATE181052T1 - Retinoesäure x-rezeptor liganden - Google Patents

Retinoesäure x-rezeptor liganden

Info

Publication number: ATE181052T1
Authority: AT; Austria
Prior art keywords: pct; retinoic acid; receptor ligands; sec; date
Prior art date: 1994-08-10

Application number

AT95930430T

Other languages

English (en)

Inventor

Michael Klaus

Allen John Lovey

Peter Mohr

Michael Rosenberger

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-08-10

Filing date

1995-07-29

Publication date

1999-06-15

1995-07-29 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

1999-06-15 Application granted granted Critical

1999-06-15 Publication of ATE181052T1 publication Critical patent/ATE181052T1/de

Links

SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 title 1
239000003446 ligand Substances 0.000 title 1
229930002330 retinoic acid Natural products 0.000 title 1
229960001727 tretinoin Drugs 0.000 title 1
230000001028 anti-proliverative effect Effects 0.000 abstract 1
230000000771 oncological effect Effects 0.000 abstract 1
150000004492 retinoid derivatives Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4056—Esters of arylalkanephosphonic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
- C07C69/533—Monocarboxylic acid esters having only one carbon-to-carbon double bond
- C07C69/56—Crotonic acid esters; Vinyl acetic acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
- C07C45/29—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
- C07C45/29—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups
- C07C45/298—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups with manganese derivatives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/63—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of halogen; by substitution of halogen atoms by other halogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
- C07C47/24—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
- C07C47/277—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
- C07C57/50—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid containing condensed ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Dermatology (AREA)
Biochemistry (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Obesity (AREA)
Diabetes (AREA)
Oncology (AREA)
Nutrition Science (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Steroid Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Paints Or Removers (AREA)

AT95930430T 1994-08-10 1995-07-29 Retinoesäure x-rezeptor liganden ATE181052T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP94112461		1994-08-10
EP95110460		1995-07-05

Publications (1)

Publication Number	Publication Date
ATE181052T1 true ATE181052T1 (de)	1999-06-15

Family

ID=26135772

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT95930430T ATE181052T1 (de)	1994-08-10	1995-07-29	Retinoesäure x-rezeptor liganden

Country Status (24)

Country	Link
US (1)	US5801253A (de)
EP (1)	EP0775103B1 (de)
JP (1)	JP2848964B2 (de)
KR (1)	KR100363545B1 (de)
CN (1)	CN1091092C (de)
AT (1)	ATE181052T1 (de)
AU (1)	AU696501B2 (de)
BR (1)	BR9508985A (de)
CA (1)	CA2196197C (de)
CY (1)	CY2170B1 (de)
CZ (1)	CZ288526B6 (de)
DE (1)	DE69510203T2 (de)
DK (1)	DK0775103T3 (de)
ES (1)	ES2133798T3 (de)
FI (1)	FI112357B (de)
GR (1)	GR3031154T3 (de)
HU (1)	HU218268B (de)
MX (1)	MX9700778A (de)
NO (1)	NO307702B1 (de)
NZ (1)	NZ292121A (de)
PL (1)	PL180048B1 (de)
RU (1)	RU2146241C1 (de)
TR (1)	TR199500976A2 (de)
WO (1)	WO1996005165A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5466861A (en) *	1992-11-25	1995-11-14	Sri International	Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors
US5968908A (en) *	1994-12-19	1999-10-19	American Cyanamid Company	Restricted 9-cis retinoids
IL116259A (en) *	1994-12-19	2000-07-16	American Cyanamid Co	Analogs of 9-cis retinoic acid and their use
US7115728B1 (en)	1995-01-30	2006-10-03	Ligand Pharmaceutical Incorporated	Human peroxisome proliferator activated receptor γ
US5675033A (en) *	1995-06-06	1997-10-07	Allergan	2,4-pentadienoic acid derivatives having retinoid-like biological activity
US6942980B1 (en)	1995-09-01	2005-09-13	Allergan, Inc.	Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities
EP0788353A1 (de)	1995-09-18	1997-08-13	Ligand Pharmaceuticals, Inc.	Ppar gamma antagonisten zur behandlung der fettleibigkeit
AU726450B2 (en)	1995-10-06	2000-11-09	Ligand Pharmaceuticals Incorporated	Dimer-selective RXR modulators and methods for their use
FR2746101B1 (fr) *	1996-03-14	1998-04-30		Composes bicycliques-aromatiques
DE69728986T2 (de) *	1996-06-21	2005-04-07	Allergan, Inc., Irvine	Substituierte tetrahydronaphthalin- und dihydronaphthalin-derivate mit einer retinoiden und/oder retinoid antagonist-ähnlichen biologischen aktivität
US5741896A (en)	1996-06-21	1998-04-21	Allergan	O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
DE69726182T2 (de)	1996-12-11	2004-08-12	Dana-Farber Cancer Institute, Inc., Boston	Methoden und pharmazeutische zusammenstellungen zur wachstumsverhinderung von tumorzellen enthaltend einen ppar-gamma agonisten und einen map kinase inhibitor
US5728846A (en)	1996-12-12	1998-03-17	Allergan	Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
US5919970A (en) *	1997-04-24	1999-07-06	Allergan Sales, Inc.	Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
WO1999005161A1 (en)	1997-07-25	1999-02-04	Ligand Pharmaceuticals Incorporated	HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARη) GENE REGULATORY SEQUENCES AND USES THEREFOR
BR9814957A (pt) *	1997-11-12	2000-10-03	Hoffmann La Roche	Tratamento de doenças imune mediadas por célula auxiliar "t" tipo 2 com antagonistas retinóides
US6242196B1 (en)	1997-12-11	2001-06-05	Dana-Farber Cancer Institute	Methods and pharmaceutical compositions for inhibiting tumor cell growth
CA2334545A1 (en) *	1998-06-12	1999-12-16	Ligand Pharmaceuticals Incorporated	Treatment of anti-estrogen resistant breast cancer using rxr modulators
US6147224A (en) *	1998-10-01	2000-11-14	Allergan Sales, Inc.	2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
US6048873A (en) *	1998-10-01	2000-04-11	Allergan Sales, Inc.	Tetrahdroquinolin-2-one 6 or 7-yl, tetrahdroquinilin-2-thione 6 or 7-yl pentadienoic acid and related derivatives having retinoid-like biological activity
US6403638B1 (en) *	1998-10-01	2002-06-11	Allergan Sales, Inc.	2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
US6326397B1 (en)	1998-11-10	2001-12-04	Hoffman-La Roche Inc.	Retinoid antagonists and use thereof
EP1212322A2 (de)	1999-08-27	2002-06-12	Ligand Pharmaceuticals Incorporated	8-substituierte-6-trifluoromethyl-9-pyrido[3,2-g]chiolinverbindungen als androgen rezeptormodulatoren
MXPA02002032A (es)	1999-08-27	2003-05-19	Ligand Pharm Inc	Compuestos moduladores del receptor de androgeno y metodos.
US6566372B1 (en)	1999-08-27	2003-05-20	Ligand Pharmaceuticals Incorporated	Bicyclic androgen and progesterone receptor modulator compounds and methods
US6593493B1 (en)	1999-09-14	2003-07-15	Ligand Pharmaceuticals, Inc.	RXR modulators with improved pharmacologic profile
ATE385421T1 (de)	2000-01-21	2008-02-15	Novartis Pharma Gmbh	Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
US6380256B1 (en)	2000-08-29	2002-04-30	Allergan Sales, Inc.	Compounds having activity as inhibitors of cytochrome P450RAI
US6313107B1 (en)	2000-08-29	2001-11-06	Allergan Sales, Inc.	Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
US6369225B1 (en)	2000-08-29	2002-04-09	Allergan Sales, Inc.	Compounds having activity as inhibitors of cytochrome P450RAI
WO2002028810A2 (en) *	2000-10-02	2002-04-11	F. Hoffmann-La Roche Ag	Retinoids for the treatment of emphysema
AU2002258550B2 (en) *	2001-03-14	2006-04-27	Eli Lilly And Company	Retinoid X receptor modulators
US6720423B2 (en) *	2002-04-30	2004-04-13	Allergan, Inc.	Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
WO2004048390A1 (en) *	2002-11-25	2004-06-10	Amedis Pharmaceuticals Ltd.	Silicon compounds
US6759547B1 (en)	2003-01-14	2004-07-06	Allergan, Inc.	5,6,7,8-tetrahydronaphthalen-2-yl 2,6-difluoroheptatrienoic acid derivatives having serum glucose reducing activity
US7019034B2 (en) *	2003-01-28	2006-03-28	Allergan, Inc.	Compositions and methods for reducing serum glucose and triglyceride levels in diabetic mammals
US6759546B1 (en)	2003-02-04	2004-07-06	Allergan, Inc.	3,5-di-iso-propyl-heptatrienoic acid derivatives having serum glucose reducing activity
US6884820B2 (en) *	2003-04-03	2005-04-26	Allergan, Inc.	5,6,7,8-tetrahydronaphthalen-2-yl-7-fluoroalkyl-heptatrienoic acid derivatives having serum glucose reducing activity
US6734193B1 (en)	2003-06-03	2004-05-11	Allergan, Inc.	(1,2,3,4-tetrahydroquinolin-8-yl)-heptatrienoic acid derivatives having serum glucose reducing activity
AU2004263156B2 (en) *	2003-08-07	2009-02-26	Allergan, Inc.	Method for treating cachexia with retinoid ligands
US6887896B1 (en)	2003-10-29	2005-05-03	Allergan, Inc.	7-[(7-Alkoxy)-chrom-3-en-6-yl]-heptatrienoic acid and 7-[(3-alkoxy)-5,6-dihydronaphthalen-2-yl]-heptatrienoic acid derivatives having serum glucose reducing activity
US9050310B2 (en)	2004-06-25	2015-06-09	Minas Theodore Coroneo	Treatment of ocular lesions
CA2622600A1 (en) *	2005-10-25	2007-05-03	Werner Bollag	Rxr agonists and antagonists, alone or in combination with ppar ligands, in the treatment of metabolic and cardiovascular diseases
US20070185055A1 (en) *	2006-02-06	2007-08-09	Guang Liang Jiang	Method for treating cachexia with retinoid ligands
US20090209601A1 (en) *	2008-02-15	2009-08-20	Wyeth	Use of rxr agonists for the treatment of osteoarthritis
JP5877466B2 (ja) *	2012-02-29	2016-03-08	国立大学法人岡山大学	テルペノイド由来レチノイド化合物
US20160263189A1 (en)	2013-10-23	2016-09-15	Acadia Pharmaceuticals Inc.	Treatment of a neurodegenerative disease or disorder
US11045441B2 (en)	2015-10-13	2021-06-29	Wisconsin Alumni Research Foundation	Use of retinoic acid and analogs thereof to treat central neural apneas
US10980725B2 (en) *	2017-09-28	2021-04-20	Johnson & Johnson Consumer Inc.	Cosmetic compositions and method of treating the skin
CN113302206A (zh)	2018-11-26	2021-08-24	戴纳立制药公司	治疗脂质代谢失调的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH651007A5 (de) *	1982-06-24	1985-08-30	Hoffmann La Roche	Polyenverbindungen.
EP0170105B1 (de) *	1984-07-07	1990-10-17	Koichi Prof. Dr. Shudo	Benzoesäurederivate
FR2613360B1 (fr) *	1987-04-03	1989-06-09	Oreal	Nouveaux derives aromatiques d'acide butyrique, leur procede de preparation et leur utilisation en medecine humaine et veterinaire ainsi qu'en cosmetique
DE69333894D1 (de) *	1992-04-22	2005-12-01	Ligand Pharm Inc	Verbindungen mit Retinoid x rezeptorselektivität
US5466861A (en) *	1992-11-25	1995-11-14	Sri International	Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors
ES2129115T3 (es) *	1993-01-11	1999-06-01	Ligand Pharm Inc	Compuestos que tienen actividad selectiva para los receptores de retinoides x, y medios para la modulacion de procesos mediados por receptores de retinoides x.
US5344959A (en) *	1993-05-18	1994-09-06	Allergan, Inc.	Tetrahydronaphthyl and cyclopropyl substituted 1,3-butadienes having retinoid-like activity

1995
- 1995-07-29 KR KR1019970700814A patent/KR100363545B1/ko not_active Expired - Fee Related
- 1995-07-29 RU RU97106022A patent/RU2146241C1/ru not_active IP Right Cessation
- 1995-07-29 PL PL95318557A patent/PL180048B1/pl not_active IP Right Cessation
- 1995-07-29 MX MX9700778A patent/MX9700778A/es not_active IP Right Cessation
- 1995-07-29 AT AT95930430T patent/ATE181052T1/de not_active IP Right Cessation
- 1995-07-29 JP JP8506962A patent/JP2848964B2/ja not_active Expired - Fee Related
- 1995-07-29 DE DE69510203T patent/DE69510203T2/de not_active Expired - Fee Related
- 1995-07-29 NZ NZ292121A patent/NZ292121A/xx unknown
- 1995-07-29 CA CA002196197A patent/CA2196197C/en not_active Expired - Fee Related
- 1995-07-29 US US08/776,087 patent/US5801253A/en not_active Expired - Fee Related
- 1995-07-29 CN CN95194064A patent/CN1091092C/zh not_active Expired - Fee Related
- 1995-07-29 ES ES95930430T patent/ES2133798T3/es not_active Expired - Lifetime
- 1995-07-29 CZ CZ1997382A patent/CZ288526B6/cs not_active IP Right Cessation
- 1995-07-29 EP EP95930430A patent/EP0775103B1/de not_active Expired - Lifetime
- 1995-07-29 WO PCT/EP1995/003021 patent/WO1996005165A1/en not_active Ceased
- 1995-07-29 DK DK95930430T patent/DK0775103T3/da active
- 1995-07-29 HU HU9700356A patent/HU218268B/hu not_active IP Right Cessation
- 1995-07-29 AU AU33821/95A patent/AU696501B2/en not_active Ceased
- 1995-07-29 BR BR9508985A patent/BR9508985A/pt not_active IP Right Cessation
- 1995-08-08 TR TR95/00976A patent/TR199500976A2/xx unknown
1997
- 1997-02-07 FI FI970547A patent/FI112357B/fi not_active IP Right Cessation
- 1997-02-07 NO NO970580A patent/NO307702B1/no unknown
1999
- 1999-09-03 GR GR990402243T patent/GR3031154T3/el unknown
2000
- 2000-05-08 CY CY0000016A patent/CY2170B1/xx unknown

Also Published As

Publication number	Publication date
FI970547L (fi)	1997-02-07
DE69510203T2 (de)	1999-12-23
CN1091092C (zh)	2002-09-18
TR199500976A2 (tr)	1996-06-21
CY2170B1 (en)	2002-08-23
CZ38297A3 (en)	1997-06-11
DK0775103T3 (da)	1999-11-15
AU696501B2 (en)	1998-09-10
NO307702B1 (no)	2000-05-15
DE69510203D1 (de)	1999-07-15
CA2196197C (en)	2007-04-17
NO970580L (no)	1997-02-07
RU2146241C1 (ru)	2000-03-10
KR970704663A (ko)	1997-09-06
FI112357B (fi)	2003-11-28
HUT76839A (en)	1997-11-28
AU3382195A (en)	1996-03-07
FI970547A0 (fi)	1997-02-07
CA2196197A1 (en)	1996-02-22
HU218268B (hu)	2000-06-28
EP0775103B1 (de)	1999-06-09
KR100363545B1 (ko)	2003-02-19
PL318557A1 (en)	1997-06-23
EP0775103A1 (de)	1997-05-28
NZ292121A (en)	1998-10-28
CN1152302A (zh)	1997-06-18
BR9508985A (pt)	1998-01-06
MX9700778A (es)	1997-05-31
JPH09512830A (ja)	1997-12-22
JP2848964B2 (ja)	1999-01-20
ES2133798T3 (es)	1999-09-16
WO1996005165A1 (en)	1996-02-22
PL180048B1 (en)	2000-12-29
US5801253A (en)	1998-09-01
NO970580D0 (no)	1997-02-07
CZ288526B6 (cs)	2001-07-11
GR3031154T3 (en)	1999-12-31

Legal Events

Date	Code	Title	Description
2000-01-15	UEP	Publication of translation of european patent specification
2010-04-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE69510203D1 (de)	1999-07-15	Retinoesäure x-rezeptor liganden
ES2148593T3 (es)	2000-10-16	Compuestos retinoides trienoicos novedosos y metodos.
ATE239465T1 (de)	2003-05-15	Verwendung von 2,7,8-trimethyl-2-( beta- carboxyethyl )-6-hydroxy-chroman (llu-alpha)
NO932672L (no)	1993-09-23	Monokloane antistoffer mot elam-1 og anvendelser derav
DE69225970D1 (de)	1998-07-23	Substituierte 2-phenyl-3-methocypropensäurenester als fungizide mittel.
DE69523022D1 (de)	2001-11-08	Verdickungsmittel enthaltende topische zusammensetzung
GR1000246B (el)	1992-05-12	Υγρες απορρυπαντικες συνθεσεις.
DK0726926T3 (da)	1999-09-20	PVDF-hæftebindemiddel, anvendelse heraf som spærremateriale samt herudfra opnåede materialer
DE69604713D1 (de)	1999-11-25	Retinoide
DE59610175D1 (de)	2003-04-03	Hydantoinderivate als zwischenprodukte für pharmazeutische wirkstoffe
ATE242236T1 (de)	2003-06-15	N-substituierte 3-azabicyclo(3.2.0)heptan- derivate als neuroleptika
PL309772A1 (en)	1996-02-05	Novel compositions based on synegically acting mixture consisting of at least one ligand specific in respect to rxr and at least one ligand specific in respect to rar-a and their application
DE19780509D2 (de)	1999-08-05	Komplexe Zubereitungen gekennzeichnet durch ein Gehalt an Betain
ES2141978T3 (es)	2000-04-01	Retinoides triciclicos, metodos para su produccion y uso.
DE69506540D1 (de)	1999-01-21	Aminosulfonsäurederivate, ihre verwendung zur herstellung von pseudopeptiden und verfahren zu ihrer herstellung
DE69323191D1 (de)	1999-03-04	Wasserlösliche retinoide
ATE397011T1 (de)	2008-06-15	Verwendung von inhibitoren von asparaginyl- endopeptidase aus säugetieren zur modulierung des immunsystemen
FR2735361B1 (fr)	1997-07-11	Compositions contenant des vesicules lipidiques renfermant des nanopigments
AR006752A1 (es)	1999-09-29	Formulaciones topicas que comprenden un vehículo topico y 3'-(l-ascorbil-2-fosforil)-colesterol ó 3'-(l-ascorbil-3- fosforil)-colesterol.